Dr. Dason on “not favoring” treatments for UTUC patients post-nephroureterectomy

“Multidisciplinary discussion is best,” says Shawn Dason, MD, FRCSC.

In this video, Shawn Dason, MD, FRCSC, discusses the takeaways of the study, “How often does cisplatin ineligibility prevent patients from receiving adjuvant therapy following radical nephroureterectomy for upper tract urothelial carcinoma?” This study was presented at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference. Dason is a urologic oncologist and an assistant professor of urology at The Ohio State University in Columbus